LH Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 5.16% compared to Labcorp Holdings's net margin of 16.64%. Labcorp Holdings's return on equity of 5.45% beat Delcath Systems's return on equity of -251.36%.

Labcorp Holdings has a consensus price target of $262.88, signalling upside risk potential of 15.38%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 86.48%. Given that Delcath Systems has higher upside potential than Labcorp Holdings, analysts believe Delcath Systems is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 1.050, which suggesting that the stock is 5.036% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.26%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 60.77% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Delcath Systems quarterly revenues of $11.2M. Labcorp Holdings's net income of $169.3M is higher than Delcath Systems's net income of $1.9M. Notably, Labcorp Holdings's price-to-earnings ratio is 44.24x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.52x versus 13.71x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics has a net margin of 5.16% compared to Labcorp Holdings's net margin of 9.08%. Labcorp Holdings's return on equity of 5.45% beat Quest Diagnostics's return on equity of 12.68%.

Labcorp Holdings has a consensus price target of $262.88, signalling upside risk potential of 15.38%. On the other hand Quest Diagnostics has an analysts' consensus of $169.77 which suggests that it could grow by 11.01%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Labcorp Holdings has a beta of 1.050, which suggesting that the stock is 5.036% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.26%. Quest Diagnostics offers a yield of 1.94% to investors and pays a quarterly dividend of $0.75 per share. Labcorp Holdings pays 60.77% of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Quest Diagnostics quarterly revenues of $2.5B. Labcorp Holdings's net income of $169.3M is lower than Quest Diagnostics's net income of $226M. Notably, Labcorp Holdings's price-to-earnings ratio is 44.24x while Quest Diagnostics's PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.52x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of 5.16% compared to Labcorp Holdings's net margin of 3.64%. Labcorp Holdings's return on equity of 5.45% beat Progyny's return on equity of 11.31%.

Labcorp Holdings has a consensus price target of $262.88, signalling upside risk potential of 15.38%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 30.14%. Given that Progyny has higher upside potential than Labcorp Holdings, analysts believe Progyny is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 1.050, which suggesting that the stock is 5.036% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.26%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 60.77% of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Progyny quarterly revenues of $286.6M. Labcorp Holdings's net income of $169.3M is higher than Progyny's net income of $10.4M. Notably, Labcorp Holdings's price-to-earnings ratio is 44.24x while Progyny's PE ratio is 24.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.52x versus 1.25x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of 5.16% compared to Labcorp Holdings's net margin of -14.42%. Labcorp Holdings's return on equity of 5.45% beat Star Equity Holdings's return on equity of -10.13%.

Labcorp Holdings has a consensus price target of $262.88, signalling upside risk potential of 15.38%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 378.47%. Given that Star Equity Holdings has higher upside potential than Labcorp Holdings, analysts believe Star Equity Holdings is more attractive than Labcorp Holdings.

Labcorp Holdings has a beta of 1.050, which suggesting that the stock is 5.036% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

Labcorp Holdings has a quarterly dividend of $0.72 per share corresponding to a yield of 1.26%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Labcorp Holdings pays 60.77% of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Labcorp Holdings quarterly revenues are $3.3B, which are larger than Star Equity Holdings quarterly revenues of $13.7M. Labcorp Holdings's net income of $169.3M is higher than Star Equity Holdings's net income of -$2M. Notably, Labcorp Holdings's price-to-earnings ratio is 44.24x while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Labcorp Holdings is 1.52x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.